2025-12-07 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. Inc. (MRK) based on the data provided, broken down into the requested sections.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Merck & Co Inc is a global pharmaceutical company that researches, develops, manufactures, and markets a wide range of healthcare products.
*   **Return Rate:**
    *   MRK Cumulative Return: 20.69%
    *   VOO (S&P 500) Cumulative Return: 100.58%
    *   Divergence: -78.1 (Relative Divergence: 20.4)
*   **Analysis of Divergence:** MRK has significantly underperformed the S&P 500 over the specified period. The divergence of -78.1 indicates a substantial difference in cumulative returns. The relative divergence of 20.4 suggests that the current divergence is relatively close to the minimum divergence that occurred, compared to the highest divergence recorded.

*   **Alpha/Beta Analysis Table & Explanation:**

    | Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
    |------------|---------|-------|--------|------|--------|
    | 2015-2017  | 1.0%    | 68.5% | -28.0% | 0.0  | 130.8  |
    | 2016-2018  | 36.0%   | 69.8% | 21.0%  | -0.0 | 177.6  |
    | 2017-2019  | 40.0%   | 69.8% | 18.0%  | 0.3  | 211.4  |
    | 2018-2020  | 16.0%   | 79.6% | -8.0%  | 0.3  | 190.1  |
    | 2019-2021  | 2.0%    | 79.6% | -44.0% | 0.7  | 186.7  |
    | 2020-2022  | 15.0%   | 79.6% | 16.0%  | 0.7  | 270.2  |
    | 2021-2023  | 33.0%   | 79.6% | 31.0%  | 0.3  | 265.5  |
    | 2022-2024  | -4.0%   | 79.6% | -25.0% | 0.2  | 242.3  |
    | 2023-2025  | -29.0%  | 71.5% | -94.0% | 1.7  | 249.1  |

    *   **CAGR:**  The Compounded Annual Growth Rate fluctuates significantly. Recent periods (2022-2025, 2023-2025) show negative growth.
    *   **MDD:** The Maximum Drawdown is consistently high, indicating substantial risk of loss during the observed periods.
    *   **Alpha:**  Alpha, which represents the excess return compared to the market, varies considerably.  Most recent period shows significant underperformance relative to the market (negative Alpha).
    *   **Beta:** Beta, measuring volatility relative to the market, is relatively low in most periods, suggesting MRK is generally less volatile than the S&P 500 *except* for the most recent period (2023-2025), where it is 1.7. This means that MRK moves 1.7x of the movement in the S&P500, and implies the stock is volatile right now.
    *   **Cap(B):** Represents the Market Cap in Billions, fluctuating with price changes.

**2) Recent Stock Price Fluctuations**

*   Current Close Price: 102.27
*   Last Market Data:
    *   Price: 99.72
    *   Previous Close: 100.89
    *   Change: -1.16
*   Moving Averages:
    *   5-day SMA: 103.03
    *   20-day SMA: 95.49
    *   60-day SMA: 88.20

*   **Analysis:** The current price (99.72) is below the 5-day SMA (103.03) but above the 20-day (95.49) and 60-day (88.20) SMAs. This suggests that while there may be some short-term downward pressure, the stock is still in an upward trend over the medium and long term. The recent change of -1.16 reflects a slight decline.

**3) RSI, PPO Index, Delta, Expected Return**

*   Market Risk Indicator (MRI): 0.8 (Medium Investment Recommended)
*   RSI: 72.30
*   PPO: 0.4967
*   Hybrid Signal:  "cash_0%_Buy 100% of cash (10 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)" (aggressive investment)
*   Recent (20 days) relative divergence change = 1.9 (+): 단기상승 (Short-term Increase)
*   Price Change: {'price': 99.72, 'previousClose': 100.89, 'change': -1.16} - Indicates a slight decline
*   Expected Return (%): -36.4 (Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.)

*   **Analysis:**
    *   The RSI of 72.30 is approaching overbought territory (above 70), suggesting the stock *may* be due for a pullback.
    *   The PPO is positive, indicating the stock price is trending upwards.
    *   The Hybrid Signal is aggressive, recommending full investment.
    *   The positive recent divergence change is in contradiction to the MRI, RSI, and expected return, and indicates that the overall models are in conflict.
    *   The large negative Expected Return is a major cause for concern.

**4) Recent News & Significant Events**

*   The news headlines present a mixed picture:
    *   Some articles highlight positive developments like a "surprise win" and FDA approval for a new product.
    *   Others focus on price declines and potential challenges.
    *   The Forbes article "Why Is Merck Stock Surging?" is contrasted by other articles highlighting price dips, showing volatility.
    *   The presence of multiple articles within a short timeframe indicates increased market attention.

*   **Impact:** This conflicting news flow suggests the market is currently uncertain about MRK's future prospects, leading to volatility in the stock price.

**4-2) Analyst Opinions**

*   **Analyst Consensus:**
    *   Key: Buy
    *   Mean (1=StrongBuy~5=Sell): 1.97 (~Buy)
    *   Opinions: 26
    *   Target Price (avg/high/low): 106.62 / 139.00 / 82.00
*   **Analysis:**
    *   The consensus rating is "Buy" with an average rating of 1.97 indicating a generally positive outlook from analysts.
    *   The target price range is broad, suggesting some uncertainty among analysts regarding the stock's potential.
    *   The lack of specific information about recent rating changes makes it difficult to assess the recent trend in analyst sentiment.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-05 | 2.32 | 17.28 B$  |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2025-11-05 | 1.25 | 16.66 B$  |

*   **Analysis:**
    *   Both EPS and revenue appear to be on a quarterly increase.
    *   The 2025-11-05 data is duplicated.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B   | 77.69%        |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $51.85B   | 11.16% |
| 2025-06-30   | $48.99B   | 9.04%  |
| 2025-03-31   | $48.34B   | 10.51% |
| 2024-12-31   | $46.31B   | 8.08%  |
| 2024-09-30   | $44.50B   | 7.09%  |

*   **Analysis:**
    *   **Revenue:** Revenue has generally increased over the last five quarters, indicating positive sales growth.
    *   **Profit Margin:**  Profit margins are exceptionally high and relatively stable, suggesting strong cost control and pricing power.
    *   **Equity:** Equity is steadily increasing, demonstrating growth in the company's net worth.
    *   **ROE:** Return on Equity is also increasing, indicating that the company is becoming more efficient at generating profits from its equity base.

**7) Comprehensive Analysis (Summary)**

Merck & Co. (MRK) presents a mixed picture based on the provided data.

*   **Negatives:**  The most concerning aspect is the significant underperformance relative to the S&P 500, coupled with a very large negative *expected* future return compared to the S&P500. Recent Alpha is highly negative and concerning.
*   **Positives:** The underlying financials appear strong, with increasing revenue, high profit margins, growing equity, and improving ROE. Analyst consensus is currently "Buy." The upward recent divergence change (of the past 20 days) is a short term plus, however, it conflicts with the negative expected return.
*   **Uncertainties:**  Conflicting news headlines and volatile stock price movements suggest market uncertainty.
*   **Recommendation:** Due to the high market drawdown and the negative expected return, MRK is not recommended as an investment.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.